Logo image of RMTI

ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RMTI - US7743743004 - Common Stock

0.8646 USD
+0.06 (+6.83%)
Last: 12/26/2025, 7:06:01 PM
0.832 USD
-0.03 (-3.77%)
After Hours: 12/26/2025, 7:06:01 PM
Fundamental Rating

2

Overall RMTI gets a fundamental rating of 2 out of 10. We evaluated RMTI against 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of RMTI is average, but there are quite some concerns on its profitability. RMTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RMTI had negative earnings in the past year.
RMTI had a negative operating cash flow in the past year.
In the past 5 years RMTI always reported negative net income.
RMTI had negative operating cash flow in 4 of the past 5 years.
RMTI Yearly Net Income VS EBIT VS OCF VS FCFRMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.60%, RMTI is in the better half of the industry, outperforming 61.62% of the companies in the same industry.
The Return On Equity of RMTI (-14.90%) is better than 63.78% of its industry peers.
Industry RankSector Rank
ROA -9.6%
ROE -14.9%
ROIC N/A
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
RMTI Yearly ROA, ROE, ROICRMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

With a Gross Margin value of 15.81%, RMTI is not doing good in the industry: 81.08% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of RMTI has grown nicely.
The Profit Margin and Operating Margin are not available for RMTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
RMTI Yearly Profit, Operating, Gross MarginsRMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

More info and screens

4

2. Health

2.1 Basic Checks

RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RMTI has been increased compared to 1 year ago.
Compared to 5 years ago, RMTI has more shares outstanding
RMTI has a better debt/assets ratio than last year.
RMTI Yearly Shares OutstandingRMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RMTI Yearly Total Debt VS Total AssetsRMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RMTI has an Altman-Z score of -7.22. This is a bad value and indicates that RMTI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.22, RMTI is not doing good in the industry: 75.14% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.26 indicates that RMTI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, RMTI is in line with its industry, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z -7.22
ROIC/WACCN/A
WACC8.23%
RMTI Yearly LT Debt VS Equity VS FCFRMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RMTI has a Current Ratio of 3.92. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.92, RMTI is doing good in the industry, outperforming 67.03% of the companies in the same industry.
A Quick Ratio of 3.50 indicates that RMTI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.50, RMTI is doing good in the industry, outperforming 68.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.92
Quick Ratio 3.5
RMTI Yearly Current Assets VS Current LiabilitesRMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

RMTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -213.73%.
The Revenue for RMTI has decreased by -23.60% in the past year. This is quite bad
RMTI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.61% yearly.
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-23.6%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%

3.2 Future

The Earnings Per Share is expected to decrease by -74.82% on average over the next years. This is quite bad
Based on estimates for the next years, RMTI will show a decrease in Revenue. The Revenue will decrease by -9.82% on average per year.
EPS Next Y-750%
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%
EPS Next 5YN/A
Revenue Next Year-32.86%
Revenue Next 2Y-14.8%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RMTI Yearly Revenue VS EstimatesRMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
RMTI Yearly EPS VS EstimatesRMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RMTI. In the last year negative earnings were reported.
Also next year RMTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RMTI Price Earnings VS Forward Price EarningsRMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RMTI Per share dataRMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

RMTI's earnings are expected to decrease with -74.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%

More info and screens

0

5. Dividend

5.1 Amount

RMTI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ROCKWELL MEDICAL INC

NASDAQ:RMTI (12/26/2025, 7:06:01 PM)

After market: 0.832 -0.03 (-3.77%)

0.8646

+0.06 (+6.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners8.57%
Inst Owner Change-43.45%
Ins Owners4.2%
Ins Owner Change-0.11%
Market Cap34.07M
Revenue(TTM)75.58M
Net Income(TTM)-5.52M
Analysts82.5
Price Target3.83 (342.98%)
Short Float %2.6%
Short Ratio2.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.49%
Min EPS beat(2)-8.93%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-45.86%
Min EPS beat(4)-198.04%
Max EPS beat(4)21.57%
EPS beat(8)5
Avg EPS beat(8)39.36%
EPS beat(12)8
Avg EPS beat(12)32.73%
EPS beat(16)12
Avg EPS beat(16)34.5%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-3.86%
Max Revenue beat(2)-3.53%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.86%
Max Revenue beat(4)6.2%
Revenue beat(8)5
Avg Revenue beat(8)1.8%
Revenue beat(12)8
Avg Revenue beat(12)2.62%
Revenue beat(16)9
Avg Revenue beat(16)0.27%
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.49%
Revenue NY rev (1m)-1.33%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.92
BVpS0.94
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.6%
ROE -14.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.81%
FCFM N/A
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score3
Asset Turnover1.31
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales 1.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.92
Quick Ratio 3.5
Altman-Z -7.22
F-Score3
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-750%
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.6%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%
Revenue Next Year-32.86%
Revenue Next 2Y-14.8%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
EBIT growth 1Y-843.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-125.54%
EBIT Next 3Y-26.07%
EBIT Next 5YN/A
FCF growth 1Y87.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.06%
OCF growth 3YN/A
OCF growth 5YN/A

ROCKWELL MEDICAL INC / RMTI FAQ

What is the ChartMill fundamental rating of ROCKWELL MEDICAL INC (RMTI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RMTI.


What is the valuation status for RMTI stock?

ChartMill assigns a valuation rating of 0 / 10 to ROCKWELL MEDICAL INC (RMTI). This can be considered as Overvalued.


How profitable is ROCKWELL MEDICAL INC (RMTI) stock?

ROCKWELL MEDICAL INC (RMTI) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for RMTI stock?

The Earnings per Share (EPS) of ROCKWELL MEDICAL INC (RMTI) is expected to decline by -750% in the next year.